These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

776 related articles for article (PubMed ID: 31226332)

  • 1. In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates.
    Chandramohan Y; Padmanaban V; Bethunaickan R; Tripathy S; Swaminathan S; Ranganathan UD
    J Glob Antimicrob Resist; 2019 Dec; 19():348-353. PubMed ID: 31226332
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Pang Y; Zong Z; Huo F; Jing W; Ma Y; Dong L; Li Y; Zhao L; Fu Y; Huang H
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
    Yang JS; Kim KJ; Choi H; Lee SH
    Ann Lab Med; 2018 Nov; 38(6):563-568. PubMed ID: 30027700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Narrative Review of Bedaquiline and Delamanid: New Arsenals Against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis.
    Ahmad Khosravi N; Sirous M; Khosravi AD; Saki M
    J Clin Lab Anal; 2024 Aug; 38(15-16):e25091. PubMed ID: 39431709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No in vitro synergistic effect of bedaquiline combined with fluoroquinolones, linezolid, and clofazimine against extensively drug-resistant tuberculosis.
    Pang Y; Jing W; Lu J; Zong Z; Huo F; Dong L; Dai G; Li Y; Huang H; Chu N
    Diagn Microbiol Infect Dis; 2019 Aug; 94(4):361-364. PubMed ID: 30876684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Study on the resistance of rifampicin-resistant Mycobacterium tuberculosis to anti-tuberculosis drugs in group A].
    Dai XW; Li CY; Wang NH; Chen SS; Tian LL; Zhao YF; Tao LY; Yang XY; Ding BC; He XX
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Nov; 46(11):1110-1117. PubMed ID: 37914422
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevalence of extensively drug-resistant tuberculosis in a Chinese multidrug-resistant TB cohort after redefinition.
    Yao C; Guo H; Li Q; Zhang X; Shang Y; Li T; Wang Y; Xue Z; Wang L; Li L; Pang Y
    Antimicrob Resist Infect Control; 2021 Aug; 10(1):126. PubMed ID: 34446095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.
    Polsfuss S; Hofmann-Thiel S; Merker M; Krieger D; Niemann S; Rüssmann H; Schönfeld N; Hoffmann H; Kranzer K
    Clin Infect Dis; 2019 Sep; 69(7):1229-1231. PubMed ID: 30933266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis.
    Wen S; Jing W; Zhang T; Zong Z; Xue Y; Shang Y; Wang F; Huang H; Chu N; Pang Y
    Eur J Clin Microbiol Infect Dis; 2019 Jul; 38(7):1293-1296. PubMed ID: 30953211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Determination of in vitro synergy by a checkerboard method when 3 core antimicrobial agents of the retreatment new scheme combined against MDR-MTB and XDR-MTB].
    Zhang LL; Yang H; Xiao HP; Lu JM; Sha W; Zhang Q
    Zhonghua Jie He He Hu Xi Za Zhi; 2016 Jun; 39(6):464-8. PubMed ID: 27289577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidrug Resistant Tuberculosis With Simultaneously Acquired Drug Resistance to Bedaquiline and Delamanid.
    Yoshiyama T; Takaki A; Aono A; Mitarai S; Okumura M; Ohta K; Kato S
    Clin Infect Dis; 2021 Dec; 73(12):2329-2331. PubMed ID: 32730621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China.
    Zheng H; He W; Jiao W; Xia H; Sun L; Wang S; Xiao J; Ou X; Zhao Y; Shen A
    BMC Infect Dis; 2021 Apr; 21(1):330. PubMed ID: 33832459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in Mycobacterium tuberculosis using the MGIT 960 system equipped with TB eXiST.
    Keller PM; Hömke R; Ritter C; Valsesia G; Bloemberg GV; Böttger EC
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4352-5. PubMed ID: 25941226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug resistance in Mycobacterium tuberculosis clinical isolates from Brazil: phenotypic and genotypic methods.
    Miyata M; Pavan FR; Sato DN; Marino LB; Hirata MH; Cardoso RF; de Melo FA; Zanelli CF; Leite CQ
    Biomed Pharmacother; 2011 Sep; 65(6):456-9. PubMed ID: 21880463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validating a 14-Drug Microtiter Plate Containing Bedaquiline and Delamanid for Large-Scale Research Susceptibility Testing of Mycobacterium tuberculosis.
    Rancoita PMV; Cugnata F; Gibertoni Cruz AL; Borroni E; Hoosdally SJ; Walker TM; Grazian C; Davies TJ; Peto TEA; Crook DW; Fowler PW; Cirillo DM;
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29941636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bedaquiline and delamanid for drug-resistant tuberculosis: a clinician's perspective.
    Guglielmetti L; Chiesi S; Eimer J; Dominguez J; Masini T; Varaine F; Veziris N; Ader F; Robert J
    Future Microbiol; 2020 Jun; 15():779-799. PubMed ID: 32700565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigating the treatment shortening potential of a combination of bedaquiline, delamanid and moxifloxacin with and without sutezolid, in a murine tuberculosis model with confirmed drug exposures.
    Walter K; Te Brake LHM; Lemm AK; Hoelscher M; Svensson EM; Hölscher C; Heinrich N
    J Antimicrob Chemother; 2024 Oct; 79(10):2607-2610. PubMed ID: 39110473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro synergistic activity of clofazimine and other antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis isolates.
    Zhang Z; Li T; Qu G; Pang Y; Zhao Y
    Int J Antimicrob Agents; 2015 Jan; 45(1):71-5. PubMed ID: 25459737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fast detection of drug interaction in Mycobacterium tuberculosis by a checkerboard resazurin method.
    Caleffi-Ferracioli KR; Maltempe FG; Siqueira VL; Cardoso RF
    Tuberculosis (Edinb); 2013 Nov; 93(6):660-3. PubMed ID: 24083948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda.
    Kabahita JM; Kabugo J; Kakooza F; Adam I; Guido O; Byabajungu H; Namutebi J; Namaganda MM; Lutaaya P; Otim J; Kakembo FE; Kanyerezi S; Nabisubi P; Sserwadda I; Kasule GW; Nakato H; Musisi K; Oola D; Joloba ML; Mboowa G
    Antimicrob Resist Infect Control; 2022 May; 11(1):68. PubMed ID: 35550202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.